Nick Stone appointed Head of Investor Relations at Fresenius
The internationally experienced healthcare and capital market expert Nick Stone has been appointed Head of Investor Relations at Fresenius, effective October 1. He will succeed Markus Georgi, who is leaving the company after nine years in this role to pursue new opportunities.
Michael Sen, CEO of Fresenius, comments: “I am delighted that we have been able to recruit Nick Stone, a recognized investor relations manager, for this important role. To ensure the long-term success of #FutureFresenius, it is vital to further strengthen the trust of investors and analysts in Fresenius globally. With his many years of experience in the healthcare industry and his excellent network in the international capital markets, Nick Stone combines decisive skills for this task. Markus Georgi has significantly developed the investor relations function at Fresenius in recent years. I would like to thank him for his great commitment and wish him all the best for his future endeavors.”
Nick Stone will start at Fresenius on October 1, 2024, and will be based in Bad Homburg, Germany. He joins Fresenius from GSK Plc (formerly GlaxoSmithKline), a global pharmaceutical company, headquartered in London, UK, where he led global investor relations as Senior Vice President since 2021. Previously, he held various roles in corporate strategy, commercial, product, and portfolio management as well as investor relations at AstraZeneca Plc. Nick Stone studied Law and Criminology at the University of Lincoln and Staffordshire University in England.
